A citation-based method for searching scientific literature

Bernard Zinman, Steven P Marso, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Ann Marie Ocampo Francisco, Jesper Barner Lekdorf, Kajsa Kvist, John B Buse. Diabetologia 2018
Times Cited: 90







List of co-cited articles
698 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Yoichiro Hirakawa, Hisatomi Arima, Sophia Zoungas, Toshiharu Ninomiya, Mark Cooper, Pavel Hamet, Giuseppe Mancia, Neil Poulter, Stephen Harrap, Mark Woodward,[...]. Diabetes Care 2014
194
36

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
32

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
728
26

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette. JAMA 2006
24

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Thomas R Pieber, Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Richard E Pratley, Vincent Woo, Simon Heller, Martin Lange,[...]. Diabetologia 2018
78
26

Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis.
Catherine Gorst, Chun Shing Kwok, Saadia Aslam, Iain Buchan, Evangelos Kontopantelis, Phyo K Myint, Grant Heatlie, Yoon Loke, Martin K Rutter, Mamas A Mamas. Diabetes Care 2015
249
23

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
22


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
302
21

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
21

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.
Antonio Ceriello, Katherine Esposito, Ludovica Piconi, Michael A Ihnat, Jessica E Thorpe, Roberto Testa, Massimo Boemi, Dario Giugliano. Diabetes 2008
758
20

Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.
Jin J Zhou, Dawn C Schwenke, Gideon Bahn, Peter Reaven. Diabetes Care 2018
64
28

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.
Louis Monnier, Claude Colette, Anne Wojtusciszyn, Sylvie Dejager, Eric Renard, Nicolas Molinari, David R Owens. Diabetes Care 2017
153
18

Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
18

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
17


Glycaemic variability in diabetes: clinical and therapeutic implications.
Antonio Ceriello, Louis Monnier, David Owens. Lancet Diabetes Endocrinol 2019
178
16

Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
962
15

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
145
15

Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study.
Justin B Echouffo-Tcheugui, Songzhu Zhao, Guy Brock, Roland A Matsouaka, David Kline, Joshua J Joseph. Diabetes Care 2019
56
25

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
872
15

The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes.
Louis Monnier, Anne Wojtusciszyn, Claude Colette, David Owens. Diabetes Technol Ther 2011
113
14

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.
John M Lachin, Ionut Bebu, Richard M Bergenstal, Rodica Pop-Busui, F John Service, Bernard Zinman, David M Nathan. Diabetes Care 2017
92
14




Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
12


Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
12

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
11

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
11

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
Itamar Raz, Peter W F Wilson, Krzysztof Strojek, Irina Kowalska, Velimir Bozikov, Anselm K Gitt, György Jermendy, Barbara N Campaigne, Lisa Kerr, Zvonko Milicevic,[...]. Diabetes Care 2009
233
10

Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
10

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).
Harpreet S Bajaj, Karri Venn, Chenglin Ye, Avril Patrick, Shivani Kalra, Hasnain Khandwala, Nadeem Aslam, David Twum-Barima, Ronnie Aronson. Diabetes Care 2017
37
24

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
239
10

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
121
10

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
10

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Sophia Zoungas, John Chalmers, Bruce Neal, Laurent Billot, Qiang Li, Yoichiro Hirakawa, Hisatomi Arima, Helen Monaghan, Rohina Joshi, Stephen Colagiuri,[...]. N Engl J Med 2014
361
10

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
103
10

Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial.
Chang-Sheng Sheng, Jingyan Tian, Ya Miao, Yi Cheng, Yulin Yang, Peter D Reaven, Zachary T Bloomgarden, Guang Ning. Diabetes Care 2020
35
25




The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
Denise E Bonds, Michael E Miller, Richard M Bergenstal, John B Buse, Robert P Byington, Jeff A Cutler, R James Dudl, Faramarz Ismail-Beigi, Angela R Kimel, Byron Hoogwerf,[...]. BMJ 2010
636
8

Glucose variability: An emerging target for the treatment of diabetes mellitus.
Simona Frontoni, Paolo Di Bartolo, Angelo Avogaro, Emanuele Bosi, Giuseppe Paolisso, Antonio Ceriello. Diabetes Res Clin Pract 2013
97
8

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.
M Muggeo, G Zoppini, E Bonora, E Brun, R C Bonadonna, P Moghetti, G Verlato. Diabetes Care 2000
194
8



Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
227
8

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
226
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.